Search results
Results from the WOW.Com Content Network
In the United States treatment with biologic drugs typically costs US$2,000 –6,000 per month, [4] compared to US$12 –600 per month for conventional (small-molecule) DMARDs. [ 27 ] References
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ v ɛ dʒ ˈ ɛ f /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration .
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their ...
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.
Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient. [ 30 ] Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.